Clinical trial guides, patient education, and research analysis to help you navigate the world of medical studies.
Comprehensive guide to 8,000+ active cancer trials — immunotherapy, ADCs, CAR-T, personalized mRNA vaccines, molecular profiling requirements, and how to find and enroll in oncology studies.
Retatrutide triple agonist Phase 3 (24.2% weight loss), oral GLP-1 programs, SGLT2i cardiorenal combinations, and stem cell beta-cell therapies for type 1 diabetes.
Alzheimer's prevention trials, presymptomatic ALS treatment (ATLAS), BTK inhibitors for progressive MS, GLP-1 neuroprotection Phase 3, and antisense oligonucleotides for rare neurological diseases.
SELECT trial semaglutide 20% MACE reduction, tirzepatide SUMMIT HFpEF results, inclisiran ORION-4 outcomes trial, Lp(a)-lowering siRNAs, and CRISPR base editing for ATTR cardiomyopathy.
RECOVER-VITAL Paxlovid Phase 3 confirms viral persistence target, 8 simultaneous RECOVER RCTs, BC007 autoantibody neutralizer, hyperbaric oxygen Phase 3, and POTS treatment platform trial.
Psilocybin Phase 3 for TRD (29% remission vs. 7.6% placebo), SAINT accelerated TMS (78.6% remission), MDMA-AT PTSD Phase 3, ibogaine for veteran PTSD, and zuranolone expanding indications.
CRISPR therapies expanding beyond SCD/beta-thal, GTX-102 ASO producing developmental milestones in Angelman syndrome, n-Lorem individualized ASOs for single patients, and basket trial designs enabling Phase 3 quality evidence with small populations.
Anti-CD19 CAR-T achieving drug-free remission in SLE and myositis Phase 2 trials, VEGA combination biologic therapy for UC, telitacicept Phase 3 for lupus, and tolebrutinib HERCULES for progressive MS.
100+ ADC Phase 1 studies, 60+ CAR-T solid tumor trials, Bayesian dose escalation replacing "3+3", in vivo CRISPR base editing programs, and how advanced cancer patients access first-in-human studies.
Step-by-step 2026 guide: searching ClinicalTrials.gov effectively, understanding eligibility criteria, navigating screening, informed consent rights, 10 questions to ask before enrolling, and what day-to-day participation involves.
KRAS G12D inhibitors (MRTX1133, HRS-4642) entering Phase 2, mRNA personalized cancer vaccines (mRNA-4157/V940) in adjuvant PDAC trials, mesothelin CAR-T, pan-KRAS inhibitors, NALIRIFOX combinations, and how patients access molecular profiling and find recruiting studies.
NIDA CTN opioid treatment trials, semaglutide and GLP-1 agonists reducing alcohol and opioid cravings (Phase 2), psilocybin for alcohol use disorder (NIAAA-funded Phase 2/3), ibogaine for opioid dependence (TBX-002), low-dose buprenorphine Bernese induction protocol, and contingency management for stimulant use.
CAR-T for childhood ALL (Kymriah, CD22-directed), ONC201 for DIPG (H3K27M DMG Phase 3 ACTION trial), GD2 CAR-T intracranial delivery, NTRK inhibitors for infantile fibrosarcoma and pediatric solid tumors, COG protocols for neuroblastoma and Ewing sarcoma, and how families find trials through Children's Oncology Group centers.
30 essential questions across 6 categories: eligibility & fit, the treatment protocol, risks & side effects, logistics, costs & compensation, and your rights. With a "why ask" explanation for each question.
Everything you need to know about clinical trials — how they work, the phases, your rights as a participant, and how to decide if a trial is right for you.
A step-by-step guide to searching ClinicalTrials.gov, understanding eligibility filters, and identifying the most relevant recruiting studies.
Understanding the four phases of clinical trials — what each phase tests, the risks involved, and what participation means at each stage.
Why eligibility criteria exist, how to read inclusion and exclusion criteria, and what to do if you don't meet the requirements.
How the NIH funds clinical research, which institutes run the most trials, and how taxpayer-funded studies translate into approved treatments.
The most actively studied drug class in medicine — oral GLP-1s, triple agonists, and new indications for obesity, diabetes, Alzheimer's, and heart failure.
CAR-T cell therapy expanding to solid tumors, personalized mRNA cancer vaccines, and next-generation checkpoint combinations.
Disease-modifying treatments, subcutaneous formulations, GLP-1 trials for cognitive protection, and prevention studies in at-risk individuals.
The NIH RECOVER program is testing 13 treatments across 8 trials. What's being studied, who qualifies, and how to enroll.
From finding a trial to signing informed consent — a complete walkthrough of the enrollment process and what to expect.
Typical compensation by trial phase, what payments cover, tax implications, and how to understand the financial aspects of participation.
Phase 1 through Phase 4 — how long each stage takes, what factors affect timelines, and your personal time commitment as a participant.
IRBs, Data Safety Monitoring Boards, adverse event reporting, stopping rules, and your rights if you experience harm.
GLP-1 agonists, anti-inflammatory drugs, and novel device-based therapies for HFpEF — the form of heart failure with the fewest approved treatments.
Oral GLP-1 agonists, triple receptor agonists, and once-weekly insulin — the next wave of diabetes treatments in late-stage trials.
CAR-T and TIL therapies for solid tumors, Phase 3 personalized mRNA vaccine trials, and next-generation checkpoint inhibitor combinations.
How AI-powered recruitment, remote monitoring, and hybrid trial designs are making clinical research more accessible regardless of geography.
How genetic testing, liquid biopsy, and biomarker requirements shape trial eligibility and what you need before applying.
The race to convert injectables to oral formulations — science, trade-offs, patient preference data, and key trials.
How to read inclusion and exclusion criteria, why they exist, the trend toward broader eligibility, and what to do when you don't qualify.
Gene therapy, alpha-synuclein antibodies, GLP-1 neuroprotection, and focused ultrasound — the most active Parkinson's research in 2026.
BTK inhibitors, remyelination therapies, stem cell trials for progressive MS, and the most promising research for patients who have run out of options.
Antibody-drug conjugates for HER2-low, psilocybin mRNA cancer vaccines for TNBC, and CDK4/6 resistance trials — the full landscape by subtype.
EGFR, KRAS, ALK targeted therapies, next-generation checkpoint inhibitors, and perioperative immunotherapy for resectable NSCLC.
TYK2 inhibitors, CAR-T cell therapy for refractory RA, and drug-free remission trials — the most important RA research in 2026.
PSMA radioligand therapy in earlier settings, actinium-225, PARP inhibitor combinations, and bispecific T cell engagers for advanced prostate cancer.
Esketamine, psilocybin Phase 3 trials, accelerated TMS, zuranolone, and anti-inflammatory approaches for treatment-resistant depression.
Dupilumab for eosinophilic COPD, itepekimab, ensifentrine, and lung regeneration research — the new era of COPD treatment.
Risankizumab, upadacitinib, combination biologic therapy, and FMT trials for patients with active or refractory Crohn's disease.
MDMA-AT Phase 3 trials, stellate ganglion block, psilocybin for PTSD, and ibogaine for veteran treatment-resistant PTSD.
SGLT2 inhibitors for non-diabetic CKD, complement inhibitors for IgA nephropathy, and wearable artificial kidney trials.
Retatrutide, cagrilintide + semaglutide, amycretin, and oral GLP-1s showing 25%+ weight loss — the next generation of obesity drugs in trials.
Head-to-head biologic comparisons, biologic discontinuation trials, itepekimab for ex-smokers, and bronchial thermoplasty innovations.
Post-resmetirom MASH pipeline, semaglutide for MASH, and RNA interference combinations targeting a functional hepatitis B cure.
Zuranolone for GAD, psilocybin for treatment-resistant anxiety, VR-based exposure therapy, and neuroinflammation-targeted approaches.
Tenecteplase replacing alteplase, extended thrombolysis windows, neuroprotective drugs in development, and brain stimulation therapies for motor recovery.
Lenacapavir showing 100% PrEP efficacy in PURPOSE trials, CAB+RPV long-acting injections, broadly neutralizing antibodies, and mRNA HIV vaccines in development.
CAR-T cell therapy producing drug-free remissions in SLE, anifrolumab expansion studies, voclosporin for lupus nephritis, and telitacicept results.
Ozanimod, etrasimod, upadacitinib, mirikizumab, and FMT trials — the expanding pipeline for patients who have failed conventional UC therapy.
ETX101 gene therapy for Dravet syndrome, fenfluramine for rare epilepsies, closed-loop neurostimulation, and trials targeting drug-resistant focal epilepsy.
Bimekizumab, risankizumab, deucravacitinib TYK2 inhibitor, and tapinarof — the new generation of psoriasis and psoriatic arthritis treatments in trials.
Atogepant and rimegepant for prevention, CGRP monoclonal antibodies, cluster headache trials, and non-invasive neuromodulation devices.
Tofersen (Qalsody) for SOD1-ALS, ATLAS pre-symptomatic trial, C9orf72 and FUS antisense oligonucleotides, and NfL biomarker-guided trial design.
PARP inhibitor maintenance, mirvetuximab soravtansine survival benefit in FRα-high patients, upifitamab rilsodotin, and immunotherapy combinations.
Pembrolizumab for MSI-H CRC, sotorasib + panitumumab for KRAS G12C, HER2-targeted therapy, and ctDNA-guided adjuvant treatment decisions.
Casgevy — the first CRISPR medicine — and Lyfgenia now approved; ongoing trials for broader access, crizanlizumab, and next-generation gene editing approaches.
Pulsed field ablation showing superior safety, CHAMPION-AF trial, factor XIa inhibitors for safer anticoagulation, and LAA closure vs. drug therapy comparisons.
KarXT (Cobenfy) — the first new mechanism in decades — emraclidine, iclepertin for cognitive impairment, and trials targeting negative symptoms.
Tirzepatide (Zepbound) FDA-approved for OSA, Nyxoah Genio bilateral stimulation, atomoxetine + oxybutynin combination, and non-CPAP alternatives in trials.
Federal protections for child participants, SMA gene therapy results, nirsevimab RSV prevention, Children's Oncology Group studies, and how parents navigate enrollment.
Low-dose naltrexone DEFEAT-FM trial, sodium oxybate for pain and sleep, rTMS protocols, and CBD trials for fibromyalgia pain management.
Zuranolone SHORELINE data for bipolar depression, ketamine for acute episodes, digital phenotyping apps, and lithium alternative research.
Why placebo controls are used, how double-blind designs work, the real science of the placebo effect, and ethical standards that protect participants.
Orphan Drug Act designations, FDA Rare Pediatric Disease priority review, basket and N-of-1 trial designs, natural history registries, and NORD resources.
What informed consent documents must cover, your unconditional right to withdraw, 10 questions to ask before signing, and how research consent differs from medical consent.
Selpercatinib (LIBRETTO-001), pralsetinib, dabrafenib/trametinib in anaplastic thyroid cancer, RAI-refractory redifferentiation strategies, and NTRK fusion trials.
Suzetrigine (VX-548), Nav1.7 inhibitors, anti-NGF antibodies, advanced spinal cord stimulation (HF10, DRG), low-dose naltrexone FIBRONALD trial, and ketamine for CRPS.
Elagolix/relugolix for endometriosis (ELARIS, SPIRIT trials), semaglutide for PCOS, uterine fibroid non-surgical options, and recurrent pregnancy loss trials.
Nivolumab/ipilimumab combinations, TIGIT/TIM-3 targets, bispecific antibodies (tarlatamab, cadonilimab), mRNA neoantigen vaccines (mRNA-4157/V940), and CAR-T solid tumor trials.
FDA-approved Rebyota and Vowst, FMT for IBD (MIRIAD trial 32% remission), precision probiotics VE303, gut-brain axis research, and microbiome-immunotherapy connection.